Market Research Logo

Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse

Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse

Summary


Pain can be classified into three main categories. Nociceptive pain involves the activation of nociceptors – neurons specialized in transmitting information regarding pain that signal to the central nervous system (CNS). Inflammatory pain results from tissue damage and activity of immune cells and the third category is pain caused by damage and/or dysfunction of the nervous system.

Pain therapeutics market is forecast to grow from US$19.7 Billion in 2016 to US$28.8 Billion in 2023 at a compound annual growth rate (CAGR) of 5.5%. The US market alone is forecast to be worth US$13.5 Billion in 2023, accounting for 45.2% of the overall pain therapeutics market. Generic products are the main source of market revenue, accounting for over 50% of total market revenue in 2016. This is due mainly to the widespread usage (particularly in the US) of generic opioids, which are far more expensive than other generic analgesics.

There are 817 products in the pain therapeutics pipeline, including 75 for migraine, 118 for inflammatory pain and 255 for neuropathic pain. Some 63% of the pipeline is in the early drug development stages. The most promising drugs within the pipeline include those drugs belonging to the new class of migraine medication, the CGRPR antagonists that have been shown to be an effective preventative therapy for migraines. This class of drugs is forecast to generate an aggregate of US$5 Billion revenue by 2023.

A total of 363 licensing deals for pain therapeutics were completed between 2006 and April 2017, with an aggregate disclosed value of US$11.8 Billion. This highlights pharmaceutical company’s interest in investment in analgesics. These deals varied considerably in terms of value, ranging from US$20,000 to US$1.5 Billion. Over 40 deals were valued at less than US$10m, while 19 were valued above US$200m.

The report “Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse” provides an introduction to the pain market, including disease epidemiology, symptoms, diagnosis, pathophysiology and co-morbidities and complications.

In depth, this report provides the following analysis -

  • Provides an overview of the landscape for pain marketed products, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyses the pain pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: migraine, inflammatory pain and neuropathic pain.
  • Detailed analysis of forecast projections to 2023 on a global level, with forecasts also provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Revenue forecasts for the major product categories are also provided.
  • Assesses the company landscape in pain, with an analysis of the key players, the types of company involved in this disease cluster, and whether this disease cluster comprises a large proportion of each company’s pipeline portfolio and total revenue.
Companies mentioned in this report: Pfizer, Depomed, Pacira, Horizon, Daiichi Sankyo, Novartis, Eli Lilly.

Scope
  • The pain therapeutics market is forecast to reach $28.8 billion in 2023. What are the key market segments driving this growth?
  • The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late stage products?
  • Despite historical high levels of generic drug development, there is a very high proportion of novel drugs in the pipeline. How do failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
  • Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
  • What licensing and co-development deals have occurred within this therapy area since 2006?
Reasons to buy
  • Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the pain therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include neuropathic pain, inflammatory pain (including osteoarthritis pain) and migraine.
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyse the pain therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at pain therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from pain therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Assess the licensing and co-development deal landscape for pain therapies.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Cluster Introduction
2.2 Symptoms
2.2.1 Migraine
2.2.2 Inflammatory pain and neuropathic pain
2.3 Diagnosis
2.4 Pathophysiology
2.4.1 Nociceptive pain transmission
2.4.2 Pain modulation in the brain
2.4.3 Inflammatory pain
2.4.4 Migraine
2.4.5 Neuropathic pain
2.5 Epidemiology
2.5.1 Migraine
2.5.2 Inflammatory pain
2.5.3 Neuropathic pain
2.6 Comorbidities and Complications
2.7 Treatment
2.7.1 Non-steroidal anti-inflammatory drugs
2.7.2 Opioid medications
2.7.3 Triptans
2.7.4 Other medications
2.7.5 Conclusion
3 Key Marketed Products
3.1 Celebrex (celecoxib) - Pfizer
3.2 Nucynta (tapentadol) - Depomed
3.3 Lyrica (pregabalin) - Pfizer
3.4 Exparel (bupivacaine) - Pacira
3.5 Voltaren (diclofenac sodium) - Novartis
3.6 Pennsaid (diclofenac sodium) - Horizon
3.7 Depakine (valproate sodium) - Daiichi Sankyo
3.8 Embeda ER (morphine sulfate + naltrexone) - Pfizer
3.9 Cymbalta (duloxetine hydrochloride) - Eli Lilly
3.10 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trial Landscape
4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type
4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type
4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type
4.5 Conclusion
4.6 Assessment of Key Pipeline Products
4.6.1 HTX-011 - Heron
4.6.2 Difelikefalin - Cara
4.6.3 Fremanezumab - Teva
4.6.4 Eptinezumab - Alder
4.6.5 Erenumab - Amgen and Novartis
4.6.6 Galcanezumab - Eli Lilly
4.6.7 Zilretta - Flexion
4.6.8 EMA-401 - Novartis
4.6.9 Conclusion
5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.2.1 Generic Opioid Usage
5.3 Revenue Forecast by Molecular Target
5.3.1 Opioid Receptors
5.3.2 Serotonin Receptors 1B and 1D
5.3.3 Prostaglandin G/H Synthase (COX)
5.3.4 Calcitonin Gene Related Peptide Receptors
5.3.5 Multiple Targets
5.3.6 Ion Channels
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Teva - Company Set to Enter the Market and Secure Large Market Share by 2023
6.1.2 Pfizer - Key Patent Expiries to Drive Negative Growth
6.1.3 Pacira - Company to Secure a Large Market Share despite Small Product Portfolio
6.1.4 Novartis - Expansion of Pain Therapeutics Portfolio for the First Time since Voltaren
6.1.5 Amgen - Company Set to Enter Pain Market in Early Forecast Period and Achieve Rapid Growth
6.1.6 Allergan - Expansion of Product Portfolio to Drive Growth
6.1.7 Depomed - Revenue to Rise despite Upcoming Patent Cliff
6.1.8 Lilly - Lilly to Expand Position in Market as Patent for Cymbalta Expires
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value and Year
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Value and Year
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type and Value
7.2.5 Co-development Deal with Disclosed Values
8 Appendix
8.1 References
8.2 List of Pipeline Products
8.3 Table of Epidemiology Forecast
8.4 Abbreviations
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Pain Therapeutics Market, Global, Approved Indications for Celebrex, 2017
Table 2: Pain Therapeutics Market, Global, Approved Indications for Nucynta, 2017
Table 3: Pain Therapeutics Market, Global, Approved Indications for Lyrica, 2017
Table 4: Pain Therapeutics Market, Global, Approved Indications for Exparel, 2017
Table 5: Pain Therapeutics Market, Global, Approved Indications for Voltaren, 2017
Table 6: Pain Therapeutics Market, Global, Approved Indications for Pennsaid, 2017
Table 7: Pain Therapeutics Market, Global, Approved Indications for Depakine, 2017
Table 8: Pain Therapeutics Market, Global, Approved Indications for Embeda ER, 2017
Table 9: Pain Therapeutics Market, Global, Approved Indications for Cymbalta, 2017
Table 10: Pain Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016
Table 11: Pain Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023
Table 12: Pain Therapeutics Market, Global, Pipeline Products, Discovery, 2017
Table 13: Pain Therapeutics Market, Global, Pipeline Products, Preclinical, 2017
Table 14: Pain Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2017
Table 15: Pain Therapeutics Market, Global, Pipeline Products, Phase I, 2017
Table 16: Pain Therapeutics Market, Global, Pipeline Products, Phase II, 2017
Table 17: Pain Therapeutics Market
Table 18: Pain Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017
Table 19: Pain Therapeutics Market, Global, Pipeline Products, Unknown, 2017
Table 20: Pain therapeutics Market, Epidemiology Patterns for Migraine, 2016-2023
Table 21: Pain therapeutics Market, Epidemiology Patterns for Post-Herpetic Neuralgia, 2016-2023
Table 22: Pain therapeutics Market, Epidemiology Patterns for Trigeminal Neuralgia, 2016-2023
Table 23: Abbreviations
1.2 List of Figures
Figure 1: Pain Therapeutics Market, Global, Epidemiology Patterns for Migraine, 2016-2023
Figure 2: Pain Therapeutics Market, Global, Epidemiology Patterns for Post-Herpetic Neuralgia, 2016-2023
Figure 3: Pain Therapeutics Market, Global, Annual Revenue for Nucynta ($m), 2015-2023
Figure 4: Pain Therapeutics Market, Global, Annual Revenue for Lyrica ($bn), 2006-2023
Figure 5: Pain Therapeutics Market, Global, Annual Revenue for Voltaren ($m), 2006-2023
Figure 6: Pain Therapeutics Market, Global, Annual Revenue for Pennsaid ($m), 2015-2023
Figure 7: Pain Therapeutics Market, Global, Annual Revenue for Depakine ($m), 2006-2023
Figure 8: Pain Therapeutics Market, Global, Annual Revenue for Embeda ER ($m), 2016-2023
Figure 9: Pain Therapeutics Market, Global, Annual Revenue for Cymbalta ($bn), 2006-2023
Figure 10: Pain Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 11: Pain Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017
Figure 12: Pain Therapeutics Market, Global, Pipeline, Key Indications by Stage of Development, 2017
Figure 13: Pain Therapeutics Market, Global, Pipeline, Key Indications by Molecule Type, 2017
Figure 14: Pain Therapeutics Market, Global, Overall Pipeline by Molecular Target, 2017
Figure 15: Pain Therapeutics Market, Global, Pipeline by Neurotransmission Molecular Target, 2017
Figure 16: Pain Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017
Figure 17: Pain Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2017
Figure 18: Pain Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target (%), 2006-2017
Figure 19: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 20: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
Figure 21: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
Figure 22: Pain Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
Figure 23: Pain Drug Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
Figure 24: Pain Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 25: Pain Therapeutics Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006-2017
Figure 26: Pain Therapeutics Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
Figure 27: Pain Therapeutics Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 28: Pain Therapeutics Market, Global, Revenue Forecast for HTX-011 ($m), 2019-2023.
Figure 29: Pain Therapeutics Market, Global, Revenue Forecast for Difelikefalin ($m), 2018-2023.
Figure 30: Pain Therapeutics Market, Global, Revenue Forecast for Fremanezumab ($m), 2018-2023
Figure 31: Pain Therapeutics Market, Global, Revenue Forecast for Eptinezumab ($m), 2018-2023
Figure 32: Pain Therapeutics Market, Global, Revenue Forecast for Erenumab ($m), 2018-2023
Figure 33: Pain Therapeutics Market, Global, Revenue Forecast for Galcanezumab ($m), 2018-2023
Figure 34: Pain Therapeutics Market, Global, Revenue Forecast for Zilretta ($m), 2017-2023
Figure 35: Pain Therapeutics Market, Global, Revenue Forecast for EMA-401 ($m), 2019-2023
Figure 36: Pain Therapeutics Market, Global, Market Size ($bn), 2016-2023
Figure 37: Pain Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023
Figure 38: Pain Therapeutics Market, Global, Annual Revenue for Generic Fentanyl ($bn), 2016-2023
Figure 39: Pain Therapeutics Market, Global, Annual Revenue for Generic Hydromorphone ($m), 2016-2023
Figure 40: Pain Therapeutics Market, Global, Annual Revenue for Generic Methadone ($m), 2016-2023
Figure 41: Pain Therapeutics Market, Global, Annual Revenue for Generic Morphine ($bn), 2016-2023
Figure 42: Pain Therapeutics Market, Global, Annual Revenue for Generic Oxycodone ($bn), 2016-2023
Figure 43: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Opioid Receptors ($bn), 2016-2023
Figure 44: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Serotonin Receptors 1B and 1D ($m), 2016-2023
Figure 45: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drug Acting on Prostaglandin Signaling ($bn), 2016-2023
Figure 46: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on CGRPR ($bn), 2016-2023
Figure 47: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Multiple Molecular Targets ($bn), 2016-2023
Figure 48: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Ion Channels ($bn), 2016-2023
Figure 49: Pain Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023
Figure 50: Pain Therapeutics Market, Global, Company Analysis Matrix, 2017
Figure 51: Pain Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 52: Pain Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 53: Pain Therapeutics Market, Global, Teva Annual Revenue Forecast, 2018-2023
Figure 54: Pain Therapeutics Market, Global, Pfizer Annual Revenue Forecast, 2016-2023
Figure 55: Pain Therapeutics Market, Global, Pacira Annual Revenue Forecast, 2016-2023
Figure 56: Pain Therapeutics Market, Global, Novartis Annual Revenue Forecast, 2016-2023
Figure 57: Pain Therapeutics Market, Global, Amgen Annual Revenue Forecast, 2018-2023
Figure 58: Pain Therapeutics Market, Global, Allergan Annual Revenue Forecast, 2016-2023
Figure 59: Pain Therapeutics Market, Global, Depomed Annual Revenue Forecast, 2016-2023
Figure 60: Pain Therapeutics Market, Global, Lilly Annual Revenue Forecast, 2016-2023
Figure 61: Pain Therapeutics Market, Global, High-Activity and Late-Stage Pipeline Developers by Type, 2017
Figure 62: Pain Therapeutics Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Specialization, 2017
Figure 63: Pain Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Pain Therapeutics, 2016-2023
Figure 64: Pain Therapeutics Market, Global, Licensing Deals by Region, Value and Year, 2006-2016
Figure 65: Pain Therapeutics Market, Global, Licensing Deals by Indication, 2006-2017
Figure 66: Pain Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 67: Pain Therapeutics Market, Global, Licensing Deals by Molecule Type, Molecular Target and Aggregate Deal Value, 2006-2017
Figure 68: Pain Therapeutics Market, Global, Licensing Deals With Disclosed Values, 2006-2017
Figure 69: Pain Therapeutics Market, Global, Co-development Deals by Region, Value and Year, 2006-2017
Figure 70: Pain Therapeutics Market, Global, Co-development Deals by Indication and Value, 2006-2017
Figure 71: Pain Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2017
Figure 72: Pain Therapeutics Market, Global, Co-development Deals by Molecule Type, Mechanism of Action and Aggregate Deal Value, 2006-2016
Figure 73: Pain Therapeutics Market, Global, Co-development Deals with Disclosed Values, 2006-2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report